進行胃癌に対するTS-1療法およびTS-1+PSK療法の第II相試験

基本情報

NCT ID: NCT00503321
ステータス: 中止
試験のフェーズ: 第2/第3相
試験タイプ: 介入
目標被験者数: 13
治験依頼者名: Eastern Network of Cancer Immunological Therapy, Japan

概要

A randomized controlled study is conducted on unresectable advanced gastric carcinoma and recurrent gastric carcinoma to compare TS-1 therapy with TS-1 + PSK therapy. The primary endpoint of this study is progression-free survival (PFS), with secondary endpoints of anticancer effect, time to treatment failure (TTF), QOL (FACT-BRM), compliance, adverse drug reactions and immunological factors.

対象疾患

Gastric Cancer

介入

Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK)(DRUG)

Tegafur/gimeracil/oteracil potassium (S-1)(DRUG)

依頼者（Sponsor）

Eastern Network Of Cancer Immunological Therapy, Japan(OTHER)

実施施設 (1)

静岡県立静岡がんセンター

Shizuoka, Shizuoka, Japan